ArriVent BioPharma, Inc.

US$13.64As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:AVBPHealthcare
Country USA
PE (Fwd) •••
TSR 3Y CAGR (15.22%)
Div yield —
ROE (53.25%)
Biotechnology
Beta (5Y) 1.66
PE TTM —
TSR TTM (27.18%)
Mkt cap US$672.6M
ROIC (35.63%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$18
29.99%
(65.62%)
Hold 1|7|5|12|7
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.32
0.32
0.31
0.34
21.75%
12.08%
(0.31%)
12.93%
Revenue$M
33.16
34.27
36.13
36.00
10.91%
8.76%
17.73%
11.02%
Peers (US$672.6M)
Cap (US$)
PE
666.5M
—
Capital
TTM
5Y
10Y
Leveragex
1.607
0.292
0.198
EBIT/Intx
0.955
0.728
0.626
Own earn%
(193.78)
(52.18)
(57.59)
Sh yield%
47.84
48.66
44.78
Owners
Insiders/Inst%
14.66
38.85
Short interest%
1.37
SBC / revenue%
2.19
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
19
Op margin range%
22–26
$1 testx
0.0
Incr. ROIC%
23